BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...

Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.

- Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - VANCOUVER, British Columbia, May 20, 2025 (GLOBE ...

(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly ...

What Is an Absence Seizure? Symptoms, Causes and More: By Shreoshree Chakrabarty Absence seizures are a type of epilepsy marked by brief lapses in awareness, often mistaken for daydreaming. Most ...

Levetiracetam reduces tonic-clonic seizures by over 77% in clinical studies. Ethosuximide is highly effective for absence seizures, especially in children. Valproate remains the gold standard for ...

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (DRUG), a biotechnology company focused on developing novel therapies for neurological and ...

Absence seizure, formerly known as petit mal seizure, is a type of short seizure that usually causes a person to briefly lose focus, stare into space, and lose awareness of their surroundings. These ...